 |
3 Diseases |  |
1 Trial |
|
1 Trial |  |
96 News |  |
| «12 |
- | Lonasen (blonanserin) / Sumitomo Dainippon
Clinical, Journal: Combination treatment with guanfacine extended release and blonanserin for Tourette's Disorder comorbid with Attention-Deficit/Hyperactivity Disorder: A case report. (Pubmed Central) - Jul 2, 2020
No abstract available
- || bromocriptine / Generic mfg., blonanserin / Generic mfg.
Retrospective data, Review, Journal: Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis. (Pubmed Central) - Jun 9, 2020
We aimed to examine the evidence from open-label studies and randomized clinical trials (RCTs) that studied four prolactin-lowering therapeutic strategies in people with psychotic disorders and hyperprolactinaemia: 1) switching to prolactin-sparing antipsychotics; 2) adding aripiprazole; 3) adding dopamine agonists; and 4) adding metformin...Nine studies explored switching antipsychotic treatment to aripiprazole (n = 4), olanzapine (n = 1), quetiapine (n = 2), paliperidone palmitate (n = 1) or blonanserin (n = 1)...Six studies explored the addition of cabergoline (n = 3), bromocriptine (n = 2) or terguride (n = 1)...The three placebo-controlled RCTs for aripiprazole addition showed similar withdrawal rates for aripiprazole (10.1%) and placebo (11.5%), without significant differences in the meta-analysis. Our study suggests that, in terms of levels of evidence, adding aripiprazole is the first option to be considered for lowering prolactin concentrations in patients with schizophrenia and hyperprolactinaemia.
- | Preclinical, Journal: Blonanserin ameliorates social deficit through dopamine-D receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia. (Pubmed Central) - Apr 26, 2020
This effect of blonanserin was antagonized by 7-OH-DPAT, a dopamine-D receptor agonist, and SCH23390, a dopamine-D receptor antagonist...These results suggest that activation of NMDA receptors due to Ser-phosphorylation of GluN1 subunit, which is a step linked to dopamine-D receptor-PKA signaling through dopamine-D receptor antagonism in the PFC, is required for the ameliorating effect of blonanserin on the PCP-induced social deficit. These findings also provide in vivo evidence that blonanserin antagonism of the dopamine-D receptors may be useful as a novel treatment strategy and that the dopamine-D receptors can be a novel therapeutic target molecule for the social deficits observed in schizophrenia.
- || risperidone / Generic mfg., blonanserin / Generic mfg.
Clinical, Journal: Risk of seizures associated with antipsychotic treatment in pediatrics with psychiatric disorders: a nested case-control study in Korea. (Pubmed Central) - Apr 9, 2020
Risperidone, aripiprazole, quetiapine, olanzapine, paliperidone, and blonanserin were independently associated with greater seizure risk. Pediatric patients receiving antipsychotics, especially new or multiple antipsychotic users, should be carefully monitored for seizure development.
- | Lonasen (blonanserin) / Sumitomo Dainippon
Preclinical, Journal: Blonanserin suppresses impulsive action in rats. (Pubmed Central) - Mar 29, 2020
1-(2-Pyriidinyl)-piperazine, an active metabolite of buspirone or tandospirone, also slightly reduced impulsive actions, though it impaired motor functions. These results affirm the validity of our strategy, but require its refinement for developing anti-impulsivity drugs.
- | Retrospective data, Journal: Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. (Pubmed Central) - Jan 22, 2020
The present observation study clearly confirmed the use of AOM should be also effective and tolerable treatment option for patients with APpoly/LAIs in the real world practice. Subsequent, adequately-powered, and well-controlled clinical trials are warranted in near future.
- | Preclinical, Journal: Characterization of binding of antipsychotics to muscarinic receptors using mouse cerebral cortex. (Pubmed Central) - Jan 11, 2020
Furthermore, the pK values of chlorpromazine, levomepromazine, zotepine, olanzapine, and clozapine overlapped with their clinically achievable blood concentrations. Therefore, the anticholinergic properties of these antipsychotics could attenuate the effects of cholinesterase inhibitors.
- || aripiprazole / Generic Mfg., olanzapine / Generic Mfg., Lonasen (blonanserin) / Sumitomo Dainippon
Clinical, Journal: Olanzapine, blonanserin, and aripiprazole associated with different frontostriatal reward system activation in patients with schizophrenia. (Pubmed Central) - Nov 15, 2019
Therefore, the anticholinergic properties of these antipsychotics could attenuate the effects of cholinesterase inhibitors. No abstract available
- | Lonasen (blonanserin) / Sumitomo Dainippon
Preclinical, Journal: Montmorillonite and Laponite Clay Materials for the Solidification of Lipid-Based Formulations for the Basic Drug Blonanserin: In Vitro and In Vivo Investigations. (Pubmed Central) - Aug 3, 2019
Importantly, the solid-state dual-loaded montmorillonite-based lipid formulation provided an optimal pharmacokinetic performance, achieving the same degree of bioavailability enhancement as the control lipid solution. These findings indicate the potential of solid-state dual-loaded clay-based lipid formulations for increasing drug loading levels and enhancing the oral absorption of poorly soluble weak base compounds.
- | Lonasen (blonanserin) / Sumitomo Dainippon
Clinical, Journal: Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study. (Pubmed Central) - Jul 31, 2019
The total cholesterol (baseline, 236.1 ± 47.6 mg/dl; endpoint [week 12], 209.9 ± 28.0 mg/dl; p = 0.005) and prolactin levels (baseline, 80.0 ± 85.2 ng/ml; endpoint [week 12], 63.2 ± 88.9 ng/ml; p = 0.003) were also significantly improved in patients with hypercholesterolemia or hyperprolactinemia. The results of the present study suggest that switching to blonanserin may be an effective strategy for schizophrenic patients unresponsive to other antipsychotic treatments.
- | Lonasen (blonanserin) / Sumitomo Dainippon
Clinical, Journal: Comparison of dopamine D3 and D2 receptor occupancies by a single dose of blonanserin in healthy subjects: A positron emission tomography study with [11C]-(+)-PHNO. (Pubmed Central) - Jul 11, 2019
A single dose of 12 mg blonanserin occupied D3 receptor to the same degree as D2 receptor in vivo. Our results were consistent with previous studies that reported that some of the pharmacological effect of blonanserin is mediated via D3 receptor antagonism.
- | Lonasen (blonanserin) / Sumitomo Dainippon
Journal: Antidepressant activities of escitalopram and blonanserin on prenatal and adolescent combined stress-induced depression model: Possible role of neurotrophic mechanism change in serum and nucleus accumbens. (Pubmed Central) - May 9, 2019
Our results were consistent with previous studies that reported that some of the pharmacological effect of blonanserin is mediated via D3 receptor antagonism. These results strongly implicate changes in BDNF levels in serum and the nucleus accumbens in the pathophysiology and treatment of early life combined stress-induced depression and highlight the therapeutic potential of escitalopram and new generation antipsychotic blonanserin for treatment-resistant refractory depression.
- |||| blonanserin / Generic mfg.
Enrollment open: Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients (clinicaltrials.gov) - Apr 16, 2019
P4, N=248, Recruiting, Sponsor: Sumitomo Pharmaceutical (Suzhou) Co., Ltd.
These results strongly implicate changes in BDNF levels in serum and the nucleus accumbens in the pathophysiology and treatment of early life combined stress-induced depression and highlight the therapeutic potential of escitalopram and new generation antipsychotic blonanserin for treatment-resistant refractory depression. Not yet recruiting --> Recruiting
- ||||| blonanserin / Generic mfg.
New P4 trial: Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients (clinicaltrials.gov) - Dec 21, 2018
P4, N=248, Not yet recruiting, Sponsor: Sumitomo Pharmaceutical (Suzhou) Co., Ltd.
- ||||||| risperidone / Generic mfg., blonanserin / Generic mfg.
Trial completion: Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone (clinicaltrials.gov) - Dec 1, 2013
P3, N=267, Completed, Sponsor: Sumitomo Pharmaceutical (Suzhou) Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||||||||| risperidone / Generic mfg., blonanserin / Generic mfg.
New P3 trial: Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone (clinicaltrials.gov) - Jan 22, 2012
P3, N=267, Completed, Sponsor: Sumitomo Pharmaceutical (Suzhou) Co., Ltd.